TH76514A - Topical antiviral formula - Google Patents
Topical antiviral formulaInfo
- Publication number
- TH76514A TH76514A TH501003173A TH0501003173A TH76514A TH 76514 A TH76514 A TH 76514A TH 501003173 A TH501003173 A TH 501003173A TH 0501003173 A TH0501003173 A TH 0501003173A TH 76514 A TH76514 A TH 76514A
- Authority
- TH
- Thailand
- Prior art keywords
- tenofovir
- purin
- ethoxymethyl
- methyl
- topical
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims abstract 5
- 229960004556 tenofovir Drugs 0.000 claims abstract 3
- 208000031886 HIV Infections Diseases 0.000 claims abstract 2
- 208000037357 HIV infectious disease Diseases 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract 2
- 241001465754 Metazoa Species 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- JMPVESVJOFYWTB-UHFFFAOYSA-N dipropan-2-yl carbonate Chemical group CC(C)OC(=O)OC(C)C JMPVESVJOFYWTB-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 230000035790 physiological processes and functions Effects 0.000 abstract 2
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000036436 anti-hiv Effects 0.000 abstract 1
- 239000003792 electrolyte Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000010839 reverse transcription Methods 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
Abstract
DC60 (03/10/48) การประดิษฐ์นี้เกี่ยวข้องกับสูตรของสารยับยั้งการถอดรหัสย้อนกลับของนิวคลีโอไทด์ (NRTls) นิยมกรด [2-(6-อะมิโน-พิวริน-9-อิล)-1-เมทิล-เอทอกซีเมทิล]-ฟอสฟอนิก (ทีโนโฟเวียร์, PMPA) หรืออุนพันธ์ฟังก์ชั่นนัลทางสรีรวิทยาของมัน ที่เหมาะสมสำหรับการใช้เฉพาะที่ และการ ใช้ในการป้องกันการติดเชื้อ HIV การประดิษฐ์นี้เกี่ยวข้องกับสูตรของสารยับยั้งการถอดรหัสย้อนกลับของนิวคลีโอไทด์ (NRTls) นิยมกรด [2-(6-อะมิโน-พิวริน-9-อิล)-1-เมทิล-เอทอกซีเมทิล]-ฟอสฟอนิก (ทีโนโฟเวียร์, PMPA) หรืออุนพันธ์ฟังก์ชั่นนัลทางสรีรวิทยาของมัน ที่เหมาะสมสำหรับการใช้เฉพาะที่ และการ ใช้ในการป้องกันการติดเชื้อ HIV สิทธิบัตรยา DC60 (03/10/48) This invention relates to a formula of reverse transcriptional inhibitors of popular nucleotides (NRTls), acid (2- (6-amino-purin-9-electrolytes). L) -1-methyl-ethoxymethyl) - phosphonic (Tenofovir, PMPA), or its physiological function Suitable for topical and prophylactic use of HIV infection, the invention involved formulations of popular nucleotide reverse transcription inhibitors (NRTls) [2- (6-amine) acids No-purin-9-il) -1-methyl-ethoxymethyl) -phosphonic (Tenofovir, PMPA), or its physiological function Suitable for topical and anti-HIV use, drug patents
Claims (3)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH76514A true TH76514A (en) | 2006-03-16 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2138163A3 (en) | Suppository formulations comprising tenofovir or tenofovir disoproxil | |
| WO2012065963A3 (en) | Antiviral condensed heterocyclic compounds | |
| IL184926A0 (en) | Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase | |
| WO2004074266A8 (en) | Hiv inhibiting 1,2,4-triazines | |
| MX374396B (en) | SUBLINGUAL FENTANYL SPRAY. | |
| WO2010084115A3 (en) | Antiviral agents | |
| WO2009017837A3 (en) | Sublingual fentanyl spray | |
| WO2010033236A3 (en) | Methods and compositions for treating bacterial infections by inhibiting quorum sensing | |
| WO2007068934A3 (en) | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit | |
| WO2011070318A3 (en) | Topical formulation | |
| WO2010068708A3 (en) | 3'-azido purine nucleotide prodrugs for treatment of viral infections | |
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| EP2196206A4 (en) | REMEDY FOR RELIEVING SKIN DISORDERS COMPRISING A MORPHINANE DERIVATIVE OR ONE OF ITS PHARMACOLOGICALLY ACCEPTABLE ACID ADDITION SALTS AS AN ACTIVE INGREDIENT | |
| WO2009099553A3 (en) | Use of kinase inhibitor in treatment of atherosclerosis | |
| WO2010130779A3 (en) | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) an antidiabetic compound for use in the treatment of proliferative diseases | |
| WO2004085682A3 (en) | Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza | |
| WO2007113243A3 (en) | Use of pde 5 inhibitors for the treatment of overactive bladder | |
| WO2007087188A8 (en) | Taste-masked tablets and granules | |
| DK1820506T3 (en) | Extended release dipyridamole formulations and process for their preparation | |
| WO2005123049A3 (en) | A pharmaceutical composition for increasing the mitochondrial genesis | |
| JP2008088189A5 (en) | ||
| TH76514A (en) | Topical antiviral formula | |
| JP2012097036A5 (en) | ||
| JP2011157392A5 (en) | ||
| EP1695969A4 (en) | ALPHA-AMINO ACID DERIVATIVES AND THEIR USE AS MEDICAMENTS |